Detalles de la búsqueda
1.
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Cancer Immunol Immunother
; 65(6): 727-40, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27098427
2.
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.
J Immunol
; 191(4): 1976-83, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23842750
3.
Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.
Int J Cancer
; 134(5): 1077-90, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23983191
4.
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
Front Immunol
; 9: 2909, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30619273
5.
Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.
Am J Cancer Res
; 6(11): 2514-2531, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27904768
6.
Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.
Oncoimmunology
; 4(4): e998107, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26137411
7.
Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells.
Oncoimmunology
; 3(10): e956579, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25941577
8.
AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.
Oncotarget
; 5(16): 6801-15, 2014 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25149535
Resultados
1 -
8
de 8
1
Próxima >
>>